Bavarian Nordic has announced that a non-disclosed country has ordered an additional 1.5 million doses of IMVANEX, a non-replicating smallpox vaccine.
While deliveries under this contract will start in 2022, the majority of the doses will be delivered during 2023 and as such this order has no impact on the financial guidance for this year.
Paul Chaplin, President and CEO of Bavarian Nordic, said: “While governments and health authorities around the world are busy fighting the current monkeypox outbreak we applaud those governments thinking beyond the current situation and building stockpiles to secure future preparedness and we are proud to assist our customers in both efforts.”
With this order, together with previously announced orders from the US and Canada, Bavarian Nordic now has significant orders of smallpox/monkeypox vaccines, providing a robust basis for 2023.